

November 13, 2025

Listing Department,  
**National Stock Exchange of India Limited**  
Exchange Plaza, 5th Floor,  
Bandra Kurla Complex,  
Mumbai-400051

**Symbol: ONYX**

Dear Sir / Madam,

**Sub: Statement of deviation or variation in utilisation of funds raised through Initial Public Offer ('IPO')**


Pursuant to Regulation 32 of the SEBI Listing Regulations and SEBI Circular No SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023, we hereby confirm that there is no deviation(s) or variation(s) in respect of the utilization of the proceeds of the Initial Public Offer ("IPO") of the Company during the half year ended September 30, 2025, as mentioned in the chapter "Object of Issue" of the Prospectus.

Kindly take the above information on records and disseminate.


Thanking You

Yours Faithfully

**For Onyx Biotec Limited**



**Sanjay Jain**  
**Managing Director**  
**DIN: 02214242**



**Sanjay Jain**  
Digitally signed  
by Sanjay Jain  
Date:  
2025.11.13  
16:22:15 +05'30'



## Annexure-B

### Statement of Deviation/Variation in utilization of funds raised through Initial Public Offer for the Half Year ended September 30, 2025

Name of listed entity	Onyx Biotec Limited
Mode of Fund Raising	IPO
Date of Raising Funds	22 November 2024
Amount Raised (Net of IPO expenses)	Rs. 2538.02 Lakhs*
Report filed for half year ended	31st March, 2025
Monitoring Agency	NA
Monitoring Agency Name, if applicable	NA
Is there a Deviation /Variation in use of funds raised	NA
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders	NA
If Yes, Date of shareholder Approval	NA
Explanation for the Deviation / Variation	NA
Comments of the Audit Committee after review	NA
Comments of the Chartered accountants, if Any	No
Objects for which funds have been raised and where there has been a deviation, in the following table	<p>Object of the Issue was:</p> <ol style="list-style-type: none"> <li>1. Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use</li> <li>2. Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections</li> <li>3. Prepayment or repayment of all or a portion of certain loans availed by our Company</li> <li>4. General corporate purposes</li> </ol> <p>We hereby confirm that there was no deviation from the objects.</p>

Original Object	Modified Object , if any	Original Allocation (INR Lakhs)	Allocation Modified Allocation, if any (INR Lakhs)	Fund Utilized (INR Lakhs)	Amount of Deviation/ Variation For the quarter According to applicable object	Remarks if Any





Upgradation of existing manufacturing Unit I to manufacture large volume parentals for intravenous use	NA	607.70	NA	148.58	Nil	Advance of INR 91.18 lakhs has been paid upto 30 <sup>th</sup> September and bills will be received once machinery is delivered and installed
Setting up a high-speed cartooning packaging line at existing manufacturing Unit II for Dry Powder Injections	NA	124.05	NA	50.23	Nil	Advance of INR 50.23 lakhs has been paid upto 30 <sup>th</sup> September and bills will be received once machinery is delivered and installed
Prepayment or repayment of all or a portion of certain loans availed by our Company	NA	1200	NA	1200	Nil	-
General corporate purposes	Yes	600	606.27*	599.42	Nil	Refer Note
<b>Total</b>		<b>2531.75</b>	<b>2538.02</b>	<b>1998.23</b>	Nil	

**\* Note**

\*During the Half ended 30 September 2025, the originally estimated issue expenses amounting to ₹402.35 lakhs have been actualized to ₹396.08 Lakhs, as per the actual invoices against original estimated issue expenses. Accordingly, net proceeds have increased from ₹2531.75 Lakhs to ₹2538.02 Lakhs and funds utilization under object "General Corporate purposes" have increased to ₹606.27 Lakhs from previously estimated amount of ₹600 Lakhs.

\* Unutilised amount of ₹ 532.94 lakhs have been invested/parked in fixed deposit with Kotak Bank

\*Unutilised amount of ₹ 6.85 lakhs have been separately kept in account created with HDFC Bank for





IPO purpose.


Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised; or
- (b) Deviation in the amount of funds actually utilized as against what was original disclosed;
- (c) Change in terms of a contract referred to in the fund raising documents i.e, prospectus, letter of offer, etc.

**For Onyx Biotec Limited**



**Sanjay Jain**  
**Managing Director**  
**DIN: 02214242**



**Sanjay  
Jain**

Digitally signed  
by Sanjay Jain  
Date: 2025.11.13  
16:22:52 +05'30'